XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Data (Tables)
 9 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Area
Revenues by segment, organizational unit and geographical areas for the three and nine-month periods are detailed below. The Company has no material intersegment revenues.
Three Months Ended June 30,
(Millions of dollars)20242023
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$670 $453 $1,123 $628 $459 $1,086 
Medication Management Solutions680 160 840 587 167 754 
Pharmaceutical Systems158 437 594 186 408 594 
Total segment revenues$1,508 $1,050 $2,558 $1,400 $1,033 $2,434 
Life Sciences
Integrated Diagnostic Solutions$405 $491 $896 $398 $460 $858 
Biosciences141 222 363 148 220 368 
Total segment revenues$546 $714 $1,260 $546 $680 $1,226 
Interventional
Surgery$283 $93 $376 $298 $90 $388 
Peripheral Intervention263 225 488 256 225 481 
Urology and Critical Care297 78 375 272 77 349 
Total segment revenues$844 $396 $1,240 $826 $392 $1,218 
Other (a)$(6)$(62)$(67)$— $— $— 
Total Company revenues$2,891 $2,098 $4,990 $2,772 $2,106 $4,878 
(a)    Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5.
Nine Months Ended June 30,
(Millions of dollars)20242023
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$1,971 $1,310 $3,282 $1,863 $1,332 $3,195 
Medication Management Solutions1,883 475 2,359 1,701 483 2,184 
Pharmaceutical Systems442 1,154 1,596 478 1,092 1,570 
Total segment revenues$4,297 $2,940 $7,237 $4,042 $2,907 $6,949 
Life Sciences
Integrated Diagnostic Solutions$1,286 $1,451 $2,737 $1,327 $1,371 $2,699 
Biosciences426 689 1,115 444 660 1,104 
Total segment revenues$1,712 $2,139 $3,852 $1,772 $2,031 $3,803 
Interventional
Surgery$851 $273 $1,124 $880 $252 $1,131 
Peripheral Intervention762 669 1,431 748 635 1,383 
Urology and Critical Care930 234 1,165 794 225 1,019 
Total segment revenues$2,543 $1,177 $3,720 $2,421 $1,112 $3,533 
Other (a)$(6)$(62)$(67)$— $— $— 
Total Company revenues $8,546 $6,195 $14,741 $8,235 $6,050 $14,285 
(a)     Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5.
Financial Information for Company's Segments
Segment income for the three and nine-month periods was as follows:
 Three Months Ended
June 30,		Nine Months Ended
June 30,
(Millions of dollars)2024202320242023
Income Before Income Taxes
Medical (a)$753 $588 $1,950 $1,783 
Life Sciences387 343 1,174 1,171 
Interventional365 323 1,044 922 
Total Segment Operating Income1,505 1,254 4,168 3,875 
Integration, restructuring and transaction expense(112)(70)(288)(175)
Net interest expense (89)(95)(265)(299)
Other unallocated items (b)(804)(618)(2,124)(1,920)
Total Income Before Income Taxes$500 $471 $1,491 $1,481 
(a)The amounts for the three and nine months ended June 30, 2023 included charges recorded to Cost of products sold of $90 million to adjust estimated future product remediation costs.
(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.